Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 15 17
Mood Disorders 55 43 44 15 72
Episodic Mood Disorder 12 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 44 D019964
NCIt 50 C92200
SNOMED-CT 68 46206005 74421008
UMLS 72 C0525045 C1456434

Summaries for Mood Disorder

MedlinePlus : 43 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to dysthymic disorder and delusional disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Pioglitazone and Amitriptyline have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature.

Wikipedia : 75 Mood disorder, also known as mood affective disorders, is a group of conditions where a disturbance in... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 dysthymic disorder 33.5 SLC6A4 MAOA HTR2A
2 delusional disorder 33.3 TH DRD4 DRD2
3 kleptomania 33.2 SLC6A4 MAOA HTR1A
4 atypical depressive disorder 33.1 SLC6A4 MAOA HTR2A CRH
5 postpartum depression 33.0 SLC6A4 MAOA CRH COMT BDNF
6 acth-secreting pituitary adenoma 32.7 POMC NR3C1 CRH
7 schizoaffective disorder 32.7 SLC6A4 HTR2A DRD2 DISC2 DISC1 COMT
8 endogenous depression 32.1 TPH1 SLC6A4 NR3C1 NPY MAOA HTR2A
9 avoidant personality disorder 31.9 TPH1 SLC6A4 MAOA
10 depression 31.8 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2A
11 bipolar i disorder 31.8 SLC6A4 HTR2A HTR1A COMT BDNF
12 social phobia 31.6 SLC6A4 MAOA HTR1A DRD2
13 traumatic brain injury 31.6 DRD2 COMT BDNF
14 bipolar disorder 31.6 TPH1 TH SLC6A4 SLC18A2 HTR2A HTR1A
15 brain injury 31.6 DRD2 COMT BDNF
16 tardive dyskinesia 31.6 HTR2A DRD2 COMT
17 agoraphobia 31.4 SLC6A4 MAOA HTR1A
18 schizophrenia 2 31.4 DISC2 DISC1
19 alexithymia 31.2 SLC6A4 HTR1A DRD2 COMT
20 phobia, specific 31.1 MAOA COMT
21 schizophreniform disorder 31.1 DRD2 COMT
22 temporal lobe epilepsy 31.1 NPY HTR1A BDNF
23 substance abuse 31.0 SLC6A4 NPY MAOA HTR1B DRD4 DRD2
24 eating disorder 31.0 SLC6A4 POMC NPY DRD2 CRH COMT
25 pathological gambling 31.0 SLC6A4 MAOA HTR2A DRD4 DRD2
26 heroin dependence 30.9 DRD4 DRD2 BDNF
27 generalized anxiety disorder 30.9 TPH1 SLC6A4 MAOA HTR2A HTR1A DRD2
28 mental depression 30.9 TPH2 TPH1 SLC6A4 POMC NR3C1 MAOA
29 panic disorder 30.8 TPH2 SLC6A4 POMC MAOA HTR2A HTR1A
30 irritable bowel syndrome 30.8 TPH1 SLC6A4 CRH
31 fibromyalgia 30.8 SLC6A4 NPY HTR2A CRH COMT
32 early-onset schizophrenia 30.8 HTR2A DRD2 BDNF
33 personality disorder 30.8 TPH1 SLC6A4 MAOA HTR2A HTR1B HTR1A
34 tobacco addiction 30.8 TPH1 SLC6A4 MAOA HTR2A DRD2 COMT
35 cocaine dependence 30.7 SLC6A4 POMC DRD2
36 autism spectrum disorder 30.7 TPH2 SLC6A4 HTR2A DISC2 BDNF
37 bulimia nervosa 30.7 SLC6A4 NPY HTR2A HTR1B COMT BDNF
38 conduct disorder 30.7 TPH1 SLC6A4 MAOA DRD4 DRD2 COMT
39 drug dependence 30.7 SLC6A4 POMC DRD2 CRH BDNF
40 anorexia nervosa 30.7 SLC6A4 POMC NPY HTR2A CRH COMT
41 post-traumatic stress disorder 30.7 SLC6A4 NR3C1 MAOA HTR2A DRD2 CRH
42 phobic disorder 30.7 SLC6A4 MAOA HTR1A COMT
43 amnestic disorder 30.7 HTR1A CREB1 BDNF
44 substance dependence 30.6 SLC6A4 POMC MAOA HTR1B DRD4 DRD2
45 serotonin syndrome 30.6 SLC6A4 MAOA HTR2A HTR1A
46 migraine with or without aura 1 30.6 TPH1 SLC6A4 MAOA HTR2A HTR1B HTR1A
47 allergic encephalomyelitis 30.6 POMC CRH
48 movement disease 30.6 TH SLC18A2 DRD2
49 intermittent explosive disorder 30.6 SLC6A4 NPY HTR1A
50 antisocial personality disorder 30.6 SLC6A4 MAOA HTR1B DRD2 COMT

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 BDNF COMT CREB1 CRH DISC1 DRD2
2 homeostasis/metabolism MP:0005376 10.36 BDNF COMT CREB1 CRH DISC1 DRD2
3 cardiovascular system MP:0005385 10.31 COMT CREB1 DRD2 HTR1A HTR1B MAOA
4 growth/size/body region MP:0005378 10.3 BDNF CREB1 CRH DISC1 DRD2 HTR1B
5 endocrine/exocrine gland MP:0005379 10.22 BDNF COMT CREB1 CRH DRD2 HTR1B
6 nervous system MP:0003631 10.22 BDNF COMT CREB1 CRH DISC1 DRD2
7 adipose tissue MP:0005375 10.13 CRH DRD2 HTR1B NPY NR3C1 POMC
8 integument MP:0010771 10.06 BDNF CRH DRD2 NR3C1 POMC SLC6A4
9 muscle MP:0005369 9.97 CREB1 DRD2 HTR1B HTR2A NR3C1 SLC18A2
10 no phenotypic analysis MP:0003012 9.91 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 normal MP:0002873 9.81 BDNF CREB1 CRH DRD2 NPY NR3C1
12 respiratory system MP:0005388 9.61 BDNF COMT CREB1 CRH DRD2 NR3C1
13 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC18A2 TPH2

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 473)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Amitriptyline Approved Phase 4 50-48-6 2160
3
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
4
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
5
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
9
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
10
Disulfiram Approved Phase 4 97-77-8 3117
11
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
12
Desipramine Approved, Investigational Phase 4 50-47-5 2995
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Ziprasidone Approved Phase 4 146939-27-7 60854
15
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
16
Ribavirin Approved Phase 4 36791-04-5 37542
17
Methohexital Approved Phase 4 151-83-7 9034
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
20
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
21
Memantine Approved, Investigational Phase 4 19982-08-2 4054
22
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
23
Infliximab Approved Phase 4 170277-31-3
24
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
25
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
26
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
27
Ledipasvir Approved Phase 4 1256388-51-8 67505836
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Suvorexant Approved, Investigational Phase 4 1030377-33-3
30
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
31
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
32
Clonidine Approved Phase 4 4205-90-7 2803
33
leucovorin Approved Phase 4 58-05-9 143 6006
34
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
35
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
36
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
37
Hydroxychloroquine Approved Phase 4 118-42-3 3652
38
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
39
Azathioprine Approved Phase 4 446-86-6 2265
40
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
41
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
42
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
43
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
44
Lorazepam Approved Phase 4 846-49-1 3958
45
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
46
Metformin Approved Phase 4 657-24-9 4091 14219
47
Sertraline Approved Phase 4 79617-96-2 68617
48
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
49
Clozapine Approved Phase 4 5786-21-0 2818
50
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 899)
# Name Status NCT ID Phase Drugs
1 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
2 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
3 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
4 Lithium in Cardiac Surgery Related Acute Kidney Injury: A Pilot Study Unknown status NCT03056248 Phase 4 Placebo oral capsule;Lithium Carbonate
5 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
6 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
7 Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
8 Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms Completed NCT00912535 Phase 4 Quetiapine extended release tablet;Placebo
9 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
10 Endogenous Opioid Activity and Affective State in Insulin Resistant Women Completed NCT02069379 Phase 4 Metformin;Placebo
11 Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study Completed NCT00177567 Phase 4 lithium carbonate;Depakote-ER;risperidone;olanzapine;paroxetine;bupropion;lamotrigine;venlafaxine;tranylcypromine;mirtazapine
12 An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER Completed NCT00211250 Phase 4 Valproic Acid and Depakote ER
13 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health Completed NCT02870283 Phase 4 Lithium;Valproic Acid;Carbamazepine
14 Dynamic Measures of Neurochemistry in Mood Disorders Completed NCT00178828 Phase 4 sertraline;bupropion
15 The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression Completed NCT00030147 Phase 4 Raloxifene;Rimostil;Transdermal Estradiol;Placebo skin patch and placebo tablets
16 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
17 Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode Completed NCT02918097 Phase 4 Lithium Carbonate;Sertraline;Nortriptyline;Risperidone
18 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health Completed NCT02901249 Phase 4 sertraline;Nortriptyline;Lithium Carbonate
19 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
20 Depakote ER in Bipolar Depression Completed NCT00186186 Phase 4 Depakote ER
21 Prolonging Remission in Depressed Elderly (PRIDE) Completed NCT01028508 Phase 4 lithium and Venlafaxine
22 Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
23 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI Completed NCT01811147 Phase 4 Selective Serotonin Reuptake Inhibitor (SSRI)
24 Minocycline for Bipolar Disorder Completed NCT01514422 Phase 4 Minocycline
25 Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation Completed NCT00188942 Phase 4 Fluoxetine+Olanzapine;Olanzapine
26 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
27 Do Antidepressants Reverse the Effects of Early Life Stress on the Brain and Thrombovascular System and Improve Psychological, Neuroendocrine, and Platelet Function: A Study of Men and Women With Childhood Abuse. Completed NCT00166114 Phase 4 Escitalopram;Desipramine
28 Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder Completed NCT00502320 Phase 4 Ramelteon;Placebo
29 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
30 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
31 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres Completed NCT00526877 Phase 4 Risperidone
32 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
33 Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial Completed NCT01431092 Phase 4 Placebo;Melatonin
34 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
35 Memantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Randomized Placebo Controlled Clinical Trial Completed NCT00305578 Phase 4 Memantine;Placebo
36 Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression Completed NCT00922064 Phase 4
37 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
38 Short-Term Versus Long-Term Treatment for Severe PMS Completed NCT00318773 Phase 4 sertraline
39 A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
40 The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Completed NCT01462058 Phase 4 Placebo
41 Acute Psychotherapy for Bipolar II Depression Completed NCT01133821 Phase 4 IPSRT plus placebo (IPSRT-PLA);IPSRT plus quetiapine
42 Prozac Treatment of Major Depression: Discontinuation Study Completed NCT00427128 Phase 4 fluoxetine;placebo
43 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
44 A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders Completed NCT00253110 Phase 4 risperidone;haloperidol
45 Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans Completed NCT00288782 Phase 4 Mirtazapine
46 Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia Completed NCT01881763 Phase 4 Ketamine;Methohexital
47 Effects of Estradiol on Neural Reward System and Depression in the Perimenopause Completed NCT02255175 Phase 4 Estradiol;Progesterone
48 Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin;Pegylated interferon and ribavirin
49 Maintenance Study for Adolescent Depression Completed NCT00508859 Phase 4 Sertraline;placebo
50 Acetaminophen for Mood and Memory Changes Associated With Prednisone Therapy Completed NCT00377364 Phase 4 Drug: Acetaminophen, Drug: Placebo

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carbamazepine
Divalproex Sodium
lamotrigine
Mood Stabilizer [EPC]
Sodium Valproate
Valproic Acid

Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

41
Brain, Cortex, Testes, Heart, Thyroid, Amygdala, Prefrontal Cortex

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 16041)
# Title Authors PMID Year
1
Prevention of mood disorder after stroke: a randomised controlled trial of problem solving therapy versus volunteer support. 38 17
31200668 2019
2
Update on Binge Eating Disorder. 17
31078199 2019
3
Occurrence of psychiatric conditions, use of psychotropic medications and its relationship with postural balance in subjects with dizziness. 17
31271579 2019
4
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 9 38
20060128 2010
5
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 9 38
19936882 2010
6
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 9 38
20072116 2010
7
Altered gene expression of histone deacetylases in mood disorder patients. 9 38
19767015 2010
8
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. 9 38
20043006 2010
9
Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. 9 38
19931869 2010
10
Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. 9 38
20010318 2010
11
Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene. 9 38
19864286 2010
12
A possible role of neuropeptide Y in depression and stress. 9 38
19782662 2010
13
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. 9 38
20016223 2010
14
Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect. 9 38
19517574 2010
15
Endocannabinoids and their role in fatty liver disease. 9 38
20460921 2010
16
kappa-Opioid receptor signaling and brain reward function. 9 38
19804796 2009
17
Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats. 9 38
19576731 2009
18
The role of beta-endorphin in the pathophysiology of major depression. 9 38
19647870 2009
19
G72/G30 (DAOA) and juvenile-onset mood disorders. 9 38
19089835 2009
20
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 9 38
19584773 2009
21
Relationships between angry-impulsive personality traits and genetic polymorphisms of the dopamine transporter. 9 38
19368898 2009
22
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 9 38
19906241 2009
23
A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. 9 38
19589503 2009
24
Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. 9 38
19376528 2009
25
Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 9 38
19375869 2009
26
Mutation screen and association analysis of the glucocorticoid receptor gene (NR3C1) in childhood-onset mood disorders (COMD). 9 38
19089807 2009
27
Management of non-motor complications in Parkinson's disease. 9 38
19711120 2009
28
Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. 9 38
19224106 2009
29
Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. 9 38
19375070 2009
30
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. 9 38
19428704 2009
31
Increased risk of suicide attempt in mood disorders and TPH1 genotype. 9 38
18977032 2009
32
Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis. 9 38
19530966 2009
33
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. 9 38
19233297 2009
34
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. 9 38
19361869 2009
35
Partial regulation of serotonin transporter function by gamma-synuclein. 9 38
19429025 2009
36
Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. 9 38
18317463 2009
37
Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. 9 38
18817811 2009
38
Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. 9 38
18704093 2009
39
Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. 9 38
18715570 2009
40
Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. 9 38
18849121 2009
41
Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. 9 38
19224413 2009
42
[BDNF measurement in stress-related mood disorders: a review of clinical studies]. 9 38
20013430 2009
43
Disruption of the circadian timing systems: molecular mechanisms in mood disorders. 9 38
19708722 2009
44
Circadian polymorphisms associated with affective disorders. 9 38
19166596 2009
45
Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. 9 38
18976638 2009
46
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. 9 38
19018231 2008
47
Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. 9 38
18574609 2008
48
The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. 9 38
19032713 2008
49
BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. 9 38
19018714 2008
50
Increased expression of splicing factor SRp20 mRNA in bipolar disorder patients. 9 38
18281098 2008

Variations for Mood Disorder

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways